Donald Morton

Summary

Affiliation: John Wayne Cancer Institute
Country: USA

Publications

  1. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012
  2. ncbi request reprint Lymphatic mapping and sentinel lymphadenectomy for melanoma: past, present, and future
    D L Morton
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, California 90404, USA
    Ann Surg Oncol 8:22S-28S. 2001
  3. pmc Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases
    Donald L Morton
    Roy E Coats Research Laboratories of the John Wayne Cancer Insstitute at Saint John s Health Center, Santa Monica, CA 90404, USA
    Ann Surg 238:538-49; discussion 549-50. 2003
  4. ncbi request reprint The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma
    D L Morton
    Sonya Valley Ghidossi Vaccine Laboratory, the Roy E Coats Research Laboratories, and the Department of Surgical Oncology, John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    Br J Dermatol 151:308-19. 2004
  5. ncbi request reprint Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma
    D L Morton
    The Sonya Valley Ghidossi Vaccine Laboratory, Roy E Coats Research Laboratories, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    Dev Biol (Basel) 116:209-17; discussion 229-36. 2004
  6. ncbi request reprint Sentinel node mapping and an International Sentinel Node Society: current issues and future directions
    Donald L Morton
    Roy E Coats Research Laboratories of the John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, California, USA
    Ann Surg Oncol 11:137S-43S. 2004
  7. ncbi request reprint Sentinel-node biopsy or nodal observation in melanoma
    Donald L Morton
    Department of Surgical Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    N Engl J Med 355:1307-17. 2006
  8. pmc Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes
    Donald L Morton
    John Wayne Center Institute, Santa Monica, CA 90404, USA
    Ann Surg 236:438-48; discussion 448-9. 2002
  9. ncbi request reprint Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy
    Mathew H Chung
    Sonya Valley Ghidossi Vaccine Laboratory of the Roy E Coats Research Laboratories of the John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    J Clin Oncol 21:313-9. 2003
  10. ncbi request reprint Serum TA90 immune complex assay can predict outcome after resection of thick (> or =4 mm) primary melanoma and sentinel lymphadenectomy
    Mathew H Chung
    Roy E Coats Research Laboratories, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, California 90404, USA
    Ann Surg Oncol 9:120-6. 2002

Research Grants

  1. POLYVALENT VACCINE--PHASE III TRIAL IN STAGE IV MELANOMA
    Donald Morton; Fiscal Year: 2002
  2. SURGERY, IMMUNOLOGY AND IMMUNOTHERAPY OF HUMAN CANCER
    Donald Morton; Fiscal Year: 2006
  3. NEW APPROACHES TO SURGICAL ONCOLOGY
    Donald Morton; Fiscal Year: 2007

Detail Information

Publications74

  1. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012
    ....
  2. ncbi request reprint Lymphatic mapping and sentinel lymphadenectomy for melanoma: past, present, and future
    D L Morton
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, California 90404, USA
    Ann Surg Oncol 8:22S-28S. 2001
    ....
  3. pmc Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases
    Donald L Morton
    Roy E Coats Research Laboratories of the John Wayne Cancer Insstitute at Saint John s Health Center, Santa Monica, CA 90404, USA
    Ann Surg 238:538-49; discussion 549-50. 2003
    ....
  4. ncbi request reprint The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma
    D L Morton
    Sonya Valley Ghidossi Vaccine Laboratory, the Roy E Coats Research Laboratories, and the Department of Surgical Oncology, John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    Br J Dermatol 151:308-19. 2004
  5. ncbi request reprint Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma
    D L Morton
    The Sonya Valley Ghidossi Vaccine Laboratory, Roy E Coats Research Laboratories, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    Dev Biol (Basel) 116:209-17; discussion 229-36. 2004
    ..0001). Cumulatively, these data represent the largest phase II experience for any cancer vaccine and indicate the clinical efficacy of stimulating a patient's endogenous immune response to melanoma...
  6. ncbi request reprint Sentinel node mapping and an International Sentinel Node Society: current issues and future directions
    Donald L Morton
    Roy E Coats Research Laboratories of the John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, California, USA
    Ann Surg Oncol 11:137S-43S. 2004
  7. ncbi request reprint Sentinel-node biopsy or nodal observation in melanoma
    Donald L Morton
    Department of Surgical Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    N Engl J Med 355:1307-17. 2006
    ..We evaluated the contribution of sentinel-node biopsy to outcomes in patients with newly diagnosed melanoma...
  8. pmc Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes
    Donald L Morton
    John Wayne Center Institute, Santa Monica, CA 90404, USA
    Ann Surg 236:438-48; discussion 448-9. 2002
    ....
  9. ncbi request reprint Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy
    Mathew H Chung
    Sonya Valley Ghidossi Vaccine Laboratory of the Roy E Coats Research Laboratories of the John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    J Clin Oncol 21:313-9. 2003
    ..This study examined anti-TA90 antibody responses with respect to the survival of patients who received adjuvant vaccine immunotherapy after resection of thick (> or = 4 mm) primary cutaneous melanoma...
  10. ncbi request reprint Serum TA90 immune complex assay can predict outcome after resection of thick (> or =4 mm) primary melanoma and sentinel lymphadenectomy
    Mathew H Chung
    Roy E Coats Research Laboratories, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, California 90404, USA
    Ann Surg Oncol 9:120-6. 2002
    ....
  11. ncbi request reprint Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine
    L Andrew Difronzo
    Sonya Valley Ghidossi Vaccine Laboratory, Roy E Coats Research Laboratories, John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    J Clin Oncol 20:3242-8. 2002
    ..Specific immune responses to tumor-associated antigens might correlate with disease-free survival (DFS) and OS in patients receiving adjuvant PV therapy for primary melanoma...
  12. pmc Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes
    Yasufumi Goto
    Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Clin Cancer Res 14:3401-7. 2008
    ..Immunohistochemical staining (IHC) using S-100p-HMB-45-, and MART-1-specific antibodies is used for detecting metastases in sentinel lymph nodes (SLN). However, improvement in IHC is needed for melanoma micrometastasis detection...
  13. ncbi request reprint Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors
    David A Litvak
    Roy E Coats Research Laboratories of the John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    J Am Coll Surg 198:27-35. 2004
    ..We hypothesized that this response might have prognostic significance independent of standard prognostic features...
  14. pmc Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine
    Hiroya Takeuchi
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    Int J Cancer 117:1032-8. 2005
    ..Overall, the study indicates survivin expression in metastatic melanomas can significantly influence disease outcome and patient responses to immunotherapy...
  15. ncbi request reprint Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes
    Jonathan H Lee
    John Wayne Cancer Institute, Santa Monica, California 90404, USA
    Clin Cancer Res 11:107-12. 2005
    ..The goals of this study are to evaluate the role of melanoma in SN immunosuppression and to assess reversibility of SN immunosuppression by a cytokine therapy...
  16. pmc CpG island methylator phenotype predicts progression of malignant melanoma
    Atsushi Tanemura
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, California 90404, USA
    Clin Cancer Res 15:1801-7. 2009
    ..Because epigenetic inactivation of TRGs also has been shown in malignant melanoma, we hypothesized the existence of a clinically significant CIMP in cutaneous melanoma progression...
  17. ncbi request reprint Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes
    Theresa G Zogakis
    Roy E Coats Research Laboratories, John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Blvd, Santa Monica, California, USA
    Ann Surg Oncol 14:1604-11. 2007
    ..A tumor-negative sentinel lymph node (SLN) does not preclude recurrence of melanoma. We hypothesized that certain patient-related and tumor factors are predictive of a worse outcome in these patients...
  18. ncbi request reprint Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine
    Robert A Wascher
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    J Clin Oncol 21:2558-63. 2003
    ....
  19. ncbi request reprint Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas
    Richard J Bleicher
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA, USA
    J Clin Oncol 21:1326-31. 2003
    ..Lymphatic mapping and sentinel lymphadenectomy (LM/SL) is standard to stage regional nodes because it is accurate and minimally morbid, yet its role for thin (<or= 1.5 mm) primary melanomas is unknown...
  20. pmc Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients
    Kazuo Koyanagi
    Department of Molecular Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    Clin Cancer Res 12:1137-43. 2006
    ....
  21. ncbi request reprint Surgical management of the groin lymph nodes in melanoma in the era of sentinel lymph node dissection
    Richard Essner
    Roy E Coats Research Laboratories, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    Arch Surg 141:877-82; discussion 882-4. 2006
    ..The surgical management of these basins is unknown for patients with tumor-positive sentinel lymph nodes (SNs)...
  22. ncbi request reprint Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma
    Eddy C Hsueh
    John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Ann Surg Oncol 11:892-9. 2004
    ..Because Canvaxin immunotherapeutic requires induction of an immune response, we hypothesized that survival would be directly correlated with cellular immune responses to Canvaxin cells prior to immunization...
  23. ncbi request reprint Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry
    Lori L Wilson
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, California 90404, USA
    Ann N Y Acad Sci 1022:317-22. 2004
    ..This novel pilot study revealed three proteins that accurately identified patients who developed recurrence after curative resection of primary melanoma...
  24. doi request reprint Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma
    Chris C Lee
    Roy E Coats Research Laboratories, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    J Clin Oncol 26:535-41. 2008
    ..Because the prognostic significance of unknown primary melanoma (MUP) is unclear, we compared clinical outcomes of patients with MUP and known primary melanoma (MKP) with regional nodal metastases...
  25. pmc Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients
    Hiroya Takeuchi
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    J Clin Oncol 22:2671-80. 2004
    ....
  26. ncbi request reprint Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma
    John C Kang
    Roy E Coats Research Laboratories of the John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    J Clin Oncol 23:4764-70. 2005
    ..This study compared the incidence of ITM after wide local excision (WLE), WLE plus SLND (SLND), or WLE plus elective lymphadenectomy (ELND) for primary melanoma...
  27. pmc Estrogen receptor-alpha methylation predicts melanoma progression
    Takuji Mori
    Department of Molecular Oncology, Division of Surgical Oncology, John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Cancer Res 66:6692-8. 2006
    ..004] and overall survival (RR, 2.31; 95% CI, 1.41-5.58; P = 0.003) in biochemotherapy patients. Hypermethylated ER-alpha is a significant factor in melanoma progression. Serum methylated ER-alpha is an unfavorable prognostic factor...
  28. ncbi request reprint Melanoma: is immunotherapy of benefit?
    Mark B Faries
    John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, California, USA
    Adv Surg 37:139-69. 2003
  29. ncbi request reprint Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases
    David A Litvak
    Division of Surgical Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, California, USA
    Ann Surg Oncol 9:148-55. 2002
    ..This study evaluated our 7-year experience treating unresectable colorectal cancer (CRC) hepatic metastases refractory to systemic 5-fluorouracil...
  30. ncbi request reprint Serum total gangliosides and TA90-IC levels: novel immunologic markers in colorectal cancer
    Carlos A Perez
    Laboratory of Glyco Immunotherapy, John Wayne Cancer Institute, Santa Monica, California 90404 23023, USA
    Cancer J 8:55-61. 2002
    ..We hypothesized that TA90-IC status and serum ganglioside levels might be useful markers and might be of prognostic significance in colorectal cancer...
  31. ncbi request reprint Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine
    Eddy C Hsueh
    Sonya Valley Ghidossi Vaccine Laboratory, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    J Clin Oncol 20:4549-54. 2002
    ..Because melanoma is immunogenic, we investigated whether a therapeutic cancer vaccine called Canvaxin (CancerVax Corporation, Carlsbad, CA) could enhance antitumor immune responses and thereby prolong survival...
  32. ncbi request reprint Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications
    Carlos A Perez
    Department of Glycoimmunotherapy, Roy E Coats Research Laboratories, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, California 90404 2302, USA
    Cancer J 8:384-94. 2002
    ....
  33. ncbi request reprint Melanoma recurrence patterns after negative sentinel lymphadenectomy
    Theresa G Zogakis
    Roy E Coats Research Laboratories, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    Arch Surg 140:865-71; discussion 871-2. 2005
    ..A tumor-negative sentinel node (SN) does not eliminate the chance of melanoma recurrence. Patterns of metastasis can be identified and characterized in patients with tumor-negative SNs...
  34. pmc Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome
    Joseph Kim
    Department of Molecular Oncology, Gastrointestinal Cancer Section, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    Ann Surg 244:113-20. 2006
    ..To determine the role of chemokine receptor (CR) expression in patients with melanoma and colorectal cancer (CRC) liver metastases...
  35. ncbi request reprint Can surgical therapy alone achieve long-term cure of melanoma metastatic to regional nodes?
    Shawn E Young
    Division of Surgical Oncology and the Roy E Coates Research Laboratories, John Wayne Cancer Institute at St John s Health Center, Santa Monica, California, USA
    Cancer J 12:207-11. 2006
    ..Few series in the literature are able to refute this assertion. We therefore examined rates of long-term (> 15-25 years) survival for patients with regional (nodal) melanoma...
  36. ncbi request reprint Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma
    Hitoe Torisu-Itakura
    Department of Molecular Therapeutics, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, California 90404, USA
    Clin Cancer Res 13:3125-32. 2007
    ..We hypothesize that the nodal profile of immunoregulatory cytokines can confirm the identity of the first tumor-draining regional node, i.e., the sentinel node (SN) and indicate its tumor status...
  37. pmc Solitary dermal melanoma: beginning or end of the metastatic process?
    Chris C Lee
    Department of Surgical Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    Ann Surg Oncol 16:578-84. 2009
    ..It is unclear whether this lesion is a subtype of primary melanoma or distant cutaneous metastasis from an unknown primary. We evaluated our large experience to determine the prognosis and optimal management of SDM...
  38. pmc mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads
    Minoru Kitago
    Department of Molecular Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    Clin Chem 55:757-64. 2009
    ..The assessment of CTCs from blood has been difficult because of lack of a good monoclonal antibody (mAb) directed against surface cell antigens to capture melanoma cells...
  39. pmc Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma
    Yasufumi Goto
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California, USA
    J Invest Dermatol 130:221-9. 2010
    ..FABP7 may function as a tumor progression gene and can be used as a potential diagnostic biomarker of early-stage melanoma systemic spreading in blood...
  40. ncbi request reprint Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas
    Hiroya Takeuchi
    Department of Molecular Oncology, Saint John s Health Center, Santa Monica, California 90404, USA
    Cancer Res 63:441-8. 2003
    ..The studies also imply that an assessment of melanoma tumor MAAs may provide a stratification factor targeted for active-specific immunotherapy...
  41. ncbi request reprint Lymphatic mapping and sentinel lymphadenectomy for primary and metastatic pulmonary malignant neoplasms
    Mark B Faries
    Roy E Coats Research Laboratories, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    Arch Surg 139:870-6; discussion 876-7. 2004
    ..Intraoperative lymphatic mapping and sentinel lymphadenectomy allows focused pathologic evaluation of a few lymph nodes that accurately stage the entire basin...
  42. ncbi request reprint Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas
    Masaru Shinozaki
    Department Molecular Oncology, Saint John s Health Center, Santa Monica, California 90404, USA
    Clin Cancer Res 10:1753-7. 2004
    ..Somatic mutations of BRAF kinase, a component of the Ras-mitogen-activated protein/extracellular signal-regulated kinase kinase-mitogen-activated protein kinase pathway, are frequently reported (>65%) in nevi and malignant melanomas...
  43. pmc Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma?
    Katharine A Yao
    Department of Surgical Oncology and the Roy E Coats Research Laboratories, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA, USA
    Ann Surg 238:743-7. 2003
    ..To determine the feasibility of sentinel lymph node mapping in local and in-transit recurrent melanoma...
  44. ncbi request reprint Immunotherapy of malignant melanoma
    Alan S Kadison
    John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Surg Clin North Am 83:343-70. 2003
    ..At present, there are no FDA-approved cancer vaccines for malignant melanoma, and the results of ongoing randomized phase III clinical trials are greatly anticipated...
  45. pmc Biological factors, tumor growth kinetics, and survival after metastasectomy for pulmonary melanoma
    Jonathan H Lee
    Division of Surgical Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA, USA
    Ann Surg Oncol 16:2834-9. 2009
    ..Because pulmonary metastasectomy can improve this statistic, we investigated clinicopathologic features and biological correlates that might be used to identify surgical candidates...
  46. ncbi request reprint Endogenous immune response to gangliosides in patients with confined prostate cancer
    Mepur H Ravindranath
    Laboratory of Glycoimmunotherapy, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    Int J Cancer 116:368-77. 2005
    ....
  47. ncbi request reprint A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients
    Mark B Faries
    John Wayne Cancer Institute, Sant Monica, CA 90404, USA
    Cancer Invest 25:285-93. 2007
    ..We compared 3 tumor markers, TA90-immune complex (TA90IC), melanoma-inhibiting activity (MIA) protein, and S100B protein in Stage III melanoma patients undergoing adjuvant vaccine immunotherapy...
  48. ncbi request reprint Significance of endogenous augmentation of antiganglioside IgM in cancer patients: potential tool for early detection and management of cancer therapy
    Mepur H Ravindranath
    Department of Glycoimmunotherapy, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404 2302, USA
    Ann N Y Acad Sci 1107:212-22. 2007
    ..This tailored approach to immunotherapy could be incorporated in postoperative adjuvant protocols...
  49. pmc The role of sentinel lymph node biopsy in the management of melanoma
    Farin Amersi
    Department of Surgical Oncology and the Roy E Coats Research Laboratories, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    Adv Surg 41:241-56. 2007
    ..The future of SLN biopsy holds promise if prospective multicenter trials confirm a survival benefit for SLN biopsy as compared with watch-and-wait observation...
  50. ncbi request reprint One hundred consecutive cases of sentinel lymph node mapping in early colorectal carcinoma: detection of missed micrometastases
    Thomas F Wood
    John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    J Gastrointest Surg 6:322-9; discussion 229-30. 2002
    ..Further studies are necessary to elucidate the clinical relevance of these micrometastases...
  51. pmc The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I)
    Mark B Faries
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA, USA
    Ann Surg Oncol 17:3324-9. 2010
    ..We hypothesized that early dissection would be associated with less morbidity than delayed dissection at the time of clinical recurrence...
  52. pmc Predictors of occult nodal metastasis in patients with thin melanoma
    Mark B Faries
    John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    Arch Surg 145:137-42. 2010
    ..We hypothesized that common clinical variables may accurately estimate the risk of nodal metastasis after wide excision and determine the need for sentinel node biopsy...
  53. pmc Age-related lymphatic dysfunction in melanoma patients
    W Charles Conway
    Department of Surgical Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA, USA
    Ann Surg Oncol 16:1548-52. 2009
    ..Furthermore, advanced age is a risk factor for in-transit disease. We hypothesized that increasing age is accompanied by alterations in lymphatic function, possibly explaining these findings...
  54. ncbi request reprint Melanoma-inhibiting activity assay predicts survival in patients receiving a therapeutic cancer vaccine after complete resection of American Joint Committee on Cancer Stage III Melanoma
    Mark B Faries
    Sonya Valley Ghidossi Vaccine Laboratory of the Roy E Coats Research Laboratories of the John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, California 90404, USA
    Ann Surg Oncol 11:85-93. 2004
    ..We examined MIA levels in the serum of stage III patients treated after surgery with a therapeutic cancer vaccine...
  55. pmc Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine
    Mark B Faries
    Sonya Valley Ghidossi Vaccine Laboratory of the Roy E Coats Research Laboratories of the John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    Clin Cancer Res 15:7029-35. 2009
    ..We sought to assess the effect of the addition of granulocyte/macrophage colony-stimulating factor (GM-CSF) to vaccination with a melanoma vaccine...
  56. ncbi request reprint Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma
    Eddy C Hsueh
    John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Ann Surg Oncol 9:486-92. 2002
    ..We hypothesized that reinduction with a more intensive vaccine regimen would re-stimulate specific immune responses that were correlated with survival after recurrence...
  57. ncbi request reprint Prognostic implications of thick (>or=4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy
    Richard Essner
    Roy E Coats Research Laboratories of the John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, California 90404, USA
    Ann Surg Oncol 9:754-61. 2002
    ..Lymphatic mapping/sentinel lymphadenectomy (LM/SL) has become a routine part of our treatment algorithm for primary melanoma, yet its role in the management of thick (>or=4-mm) lesions is unknown...
  58. ncbi request reprint Effect of lymphatic mapping on the new tumor-node-metastasis classification for colorectal cancer
    Anton J Bilchik
    Division of Surgical Oncology, John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    J Clin Oncol 21:668-72. 2003
    ..This study examined the role of lymphatic mapping (LM) in the application of the new tumor-node-metastasis (TNM) classification for MM and ITC...
  59. ncbi request reprint The use of molecular profiling of early colorectal cancer to predict micrometastases
    Anton J Bilchik
    Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    Arch Surg 137:1377-83. 2002
    ..Lymphatic mapping followed by focused analysis of the sentinel node is highly accurate in identifying micrometastases...
  60. pmc Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial
    Donald L Morton
    John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    Ann Surg 242:302-11; discussion 311-3. 2005
    ....
  61. ncbi request reprint Gangliosides of organ-confined versus metastatic androgen-receptor-negative prostate cancer
    Mepur H Ravindranath
    Laboratory of Glycoimmunotherapy, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404 2302, USA
    Biochem Biophys Res Commun 324:154-65. 2004
    ..G2a-reactive ganglioside, two alkali-susceptible, and three alkali-resistant GMR17-reactive gangliosides makes HH870 a potential component of a polyvalent-vaccine for active-specific immunotherapy of CaP...
  62. ncbi request reprint Immunogenic gangliosides in human ovarian carcinoma
    Mepur H Ravindranath
    Laboratory of Glycoimmunotherapy, John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404 2302, USA
    Biochem Biophys Res Commun 353:251-8. 2007
    ..The significance of the endogenous IgM response to GD1a may be to eliminate this immunosuppressive-ganglioside from the tumor-microenvironment...
  63. ncbi request reprint Androgen blockade enhances response to melanoma vaccine
    Eddy C Hsueh
    Department of Surgical Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    J Surg Res 110:393-8. 2003
    ....
  64. ncbi request reprint Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes
    Christine T Kuo
    Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    J Clin Oncol 21:3566-72. 2003
    ..The purpose of this study was to develop a multimarker RT-PCR assay for assessing melanoma patients' archived paraffin-embedded (PE) SLNs...
  65. ncbi request reprint Cryosurgical ablation of liver tumors in colon cancer patients increases the serum total ganglioside level and then selectively augments antiganglioside IgM
    Mepur H Ravindranath
    Laboratory of Glycoimmunotherapy, John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404 2302, USA
    Cryobiology 45:10-21. 2002
    ..The post-CSA decline in the STG level correlated with the increase in the antibodies, suggesting a homeostatic role of the antibodies...
  66. ncbi request reprint Contemporary surgical treatment of advanced-stage melanoma
    Richard Essner
    Roy E Coats Research Laboratories, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    Arch Surg 139:961-6; discussion 966-7. 2004
    ..Specific clinicopathologic factors are predictive of survival following curative surgery...
  67. ncbi request reprint Immune responses in the draining lymph nodes against cancer: implications for immunotherapy
    Suyu Shu
    Center for Surgery Research, The Cleveland Clinic Foundation, Cleveland, OH, USA
    Cancer Metastasis Rev 25:233-42. 2006
    ..A clinical trial is now being carried out to test the immunogenicity and therapeutic effects of fusion hybrids for the treatment of metastatic melanoma...
  68. ncbi request reprint New TNM melanoma staging system: linking biology and natural history to clinical outcomes
    Charles M Balch
    Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Semin Surg Oncol 21:43-52. 2003
    ....
  69. ncbi request reprint Human antiganglioside autoantibodies: validation of ELISA
    Mepur H Ravindranath
    Laboratory of Glycoimmunotherapy, John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404 2302, USA
    Ann N Y Acad Sci 1050:229-42. 2005
    ..The validated protocol also must include a simple formula to estimate titers for several replicas. Finally, antibody titers must be converted to natural logs for statistical appraisal...
  70. ncbi request reprint Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial
    Anton J Bilchik
    Department of Gastrointestinal Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, and Michigan State University McLaren Regional Medical Center, Flint, MI, USA
    Ann Surg 246:568-75; discussion 575-7. 2007
    ..6% rate of micrometastases (MM) identified by immunohistochemical staining (IHC) of H&E-negative SNs in CC. We hypothesized that these MM have prognostic importance...
  71. ncbi request reprint The promise of metastasectomy in melanoma
    Mark B Faries
    Ann Surg Oncol 13:607-9. 2006
  72. ncbi request reprint Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node
    Alistair J Cochran
    Department of Pathology and Laboratory Medicine, School of Public Health at UCLA, Los Angeles, CA 90095 1732, USA
    Mod Pathol 17:747-55. 2004
    ..0001, Breslow, P=0.0001 and dendritic cell density, P=0.0007) and death from melanoma (tumor burden, P=0.0001, Breslow, P=0.0001 and dendritic cell density, P=0.0026)...
  73. ncbi request reprint Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study
    Sandra L Wong
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Ann Surg Oncol 13:809-16. 2006
    ..This multi-institutional study was undertaken to characterize patterns of failure and survival rates in these patients and to compare results with those of positive-SLN patients who underwent CLND...
  74. ncbi request reprint An evidence-based staging system for cutaneous melanoma
    Charles M Balch
    American Society of Clinical Oncology, Alexandria, VA, USA
    CA Cancer J Clin 54:131-49; quiz 182-4. 2004
    ..6) A new convention was implemented for defining clinical and pathological staging so as to take into account the new staging information gained from lymphatic mapping and sentinel node biopsy...

Research Grants9

  1. POLYVALENT VACCINE--PHASE III TRIAL IN STAGE IV MELANOMA
    Donald Morton; Fiscal Year: 2002
    ..Determine whether there is any correlation between such responses and the clinical course of vaccine patients in a prospective multicenter trial. ..
  2. SURGERY, IMMUNOLOGY AND IMMUNOTHERAPY OF HUMAN CANCER
    Donald Morton; Fiscal Year: 2006
    ..All projects rely upon the support of four cores: Administrative and Clinical Support Services, Biostatistics, Serum, Lymphocyte and Tissue Collection, and Molecular Support. ..
  3. NEW APPROACHES TO SURGICAL ONCOLOGY
    Donald Morton; Fiscal Year: 2007
    ..abstract_text> ..